Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a transplant drug help fight glioblastoma?

NCT ID NCT04477200

Ongoing Disease control Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether adding the drug mycophenolate mofetil (MMF) to standard radiation therapy is safe for people with glioblastoma, an aggressive brain cancer. About 68 participants with newly diagnosed or recurrent glioblastoma will receive different doses of MMF along with radiation. The main goals are to find the highest safe dose and to measure how much drug reaches the tumor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Mycophenolate mofetil (MMF), an immunosuppressant drug, combined with radiation therapy
What this could lead to
If successful, this could point toward a new way to treat glioblastoma by making radiation more effective.
What could go wrong
This is a very early (phase 0/1) trial with only 68 people, so it is mainly about safety and dosing. It may not lead to a proven treatment, and side effects from the drug or radiation could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED ASTROCYTOMA, GRADE IV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEWLY DIAGNOSED ASTROCYTOMA, GRADE IV NEWLY DIAGNOSED GLIOBLASTOMA NEWLY DIAGNOSED GLIOSARCOMA RECURRENT ASTROCYTOMA, GRADE IV RECURRENT GLIOBLASTOMA RECURRENT GLIOSARCOMA

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.